Catherine E. Hanratty

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Liam G. Heaney, John Busby, Catherine E. Hanratty et al. · The Lancet Respiratory Medicine · 2020 · 129 citations · Full text

Exacerbation Profile and Risk Factors in a Type-2–Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes

P. Jane McDowell, John Busby, Catherine E. Hanratty et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 80 citations · Full text

An Investigation Into the Use of mHealth in Musculoskeletal Physiotherapy: Scoping Review

Jonathon M R Agnew, Catherine E. Hanratty, Joseph G. McVeigh et al. · JMIR Rehabilitation and Assistive Technologies · 2022 · 42 citations · Full text

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial

Catherine E. Hanratty, John G. Matthews, Joseph R. Arron et al. · Trials · 2018 · 31 citations · Full text

Physical Therapists' Perceptions and Use of Exercise in the Management of Subacromial Shoulder Impingement Syndrome: Focus Group Study

Catherine E. Hanratty, Daniel Kerr, Iseult Wilson et al. · Physical Therapy · 2016 · 25 citations · Full text